Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 365

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Patient-Reported Outcomes: The Example of Health-Related Quality of Life—a European Guidance Document for the Improved Integration of Health-Related Quality of Life Assessment in the Drug Regulatory Process

For the European Regulatory Issues on Quality of Life Assessment Group, Chassany, Olivier, Sagnier, Pierre, Marquis, Patrick, Fullerton, Steve, Aaronson, Neil·2002·Drug Information Journal
DOI 10.1177/009286150203600127
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/009286150203600127

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Research works printed but not linked: 103

  1. Johnson JR, Temple R. Food and Drug Administration requirements for approval of new anticancer drugs. Cancer Treat Rep 1985;69:1155–1159.
  2. Lohr KN, Aaronson NK, Alonso J, Bumam MA, Patrick DL, Perrin EB, Roberts JS. Evaluating quality-of-life and health status instruments: Development of scientific review criteria. Clin Ther 1996;18:979–992. · DOI · Paper page
  3. Scientific Advisory Committee. Instrument Review Criteria. Med Outcomes Trust Bull 1995;3:I–IV.
  4. Staquet M, Berzon R, Osoba D, Machin D. Guidelines for reporting results of quality of life assessments in clinical trials. Qual Life Res 1996;5:496–500. · DOI · Paper page
  5. Fayers PM, Hopwood P, Harvey A, Girling DJ, Machin D, Stephens R, on Behalf of the MR. Cancer Trials Office. Quality of Life Assessment in Clinical Trials—Guidelines and a Checklist for Protocol Writers: The U. Medical Research Council Experience. Eur J Cancer 1997;33:20–28. · DOI · Paper page
  6. Revicki DA, Leidy NK, Geneste B. Recommendations for evaluating the validity of quality of life claims for labeling and promotion. Value Health 1999;2:113–127. · DOI · Paper page
  7. Smith N. Quality of life studies from the perspective of an FD. reviewing statistician. Drug Inf J 1993;27:617–623. · doi:10.1177/009286159302700306
  8. Sanders C, Egger M, Donovan J, Tallon D, Frankel S. Reporting on quality of life in randomised controlled trials: Bibliographic study. Br Med J 1998;317:1191–1194. · DOI · Paper page
  9. Chassany O, Bergmann JF, Caulin C. Reporting on quality of life in randomised controlled trials. Br Med J 1999:318:1142. · doi:10.1136/bmj.318.7175.59
  10. Kong SX, Gandhi SK. Methodologic assessments of quality of life measures in clinical trials. Ann Pharmacother 1997;31:830–836. · DOI
  11. Brown RS. Strategies and pitfalls in quality of life research. Hepatology 1999;29(Suppl. 1):9S–12S.
  12. de Haes J, Curran D, Young T, Bottomley A, Flechtner H, Aaronson N, Blazeby J, Bjordal K, Brandberg Y, Greimel E, Maher J, Sprangers M, Cull A. Quality of life evaluation in oncological clinical trials—the EORTC model. The EORTC quality of life study group. Eur J Cancer 2000;36:821–825. · doi:10.1016/s0959-8049(00)00007-1
  13. Chassany O. Does dehydroepiandrosterone improve well-being? Presse Med. 2000;29:1354–1355.
  14. Schipper H, Clinch J, Powell V. Definition and Conceptual Issues. In: Spilker B, ed. Quality of Life Assessments in Clinical Trials. New York, NY: Raven Press; 1990:11–24.
  15. Spitzer WO. State of science 1986: Quality of life and functional status as target variables for research. J Chronic Diseases 1987;6:465–471. · DOI · Paper page
  16. Sullivan M, Karlsson J, Taft C. How to Assess Quality of Life in Medicine: Rationale and Methods. In: B Guy-Grand, G Ailhaud, eds. Progress in Obesity Research:8. London: Libbey; 1999:749–755.
  17. World Health Organization. World Health Organization Constitution. Basic Documents. Geneva, Switzerland: World Health Organization; 1948.
  18. Patrick DL, Erickson P. Health Status and Health Policy: Allocating Resources to Health Care. New York, NY: Oxford University Press; 1993.
  19. Burke L. Acceptable evidence for pharmaceutical advertising and labeling, DIA Workshop on Pharmacoeconomic and Quality of Life Labeling and Marketing Claims, October 3, 2000, New Orleans, LA.
  20. Aaronson NK. Quality of life assessment in clinical trials: Methodologic issues. Control Clin Trials 1989;10:S195–S208. · DOI · Paper page
  21. Testa MA, Simonson DC. Assessment of quality of life outcomes. N Engl J Med 1996:334:835–840. · DOI · Paper page
  22. Revicki DA, Ehreth JL. Health-related quality-of-life assessment and planning for the pharmaceutical industry. Clin Ther 1997;19:1101–1115. · DOI
  23. Feinstein AR. Clinimetric perspectives. J Chronic Diseases 1987;40:635–640. · DOI
  24. Bulpitt CJ, Fletcher AE. The measurement of quality of life in hypertensive patients: A practical approach. Br J Clin Pharmacol 1990;30:353–364. · DOI
  25. Wiklund I, Dimenäs E, Wahl M. Factors of importance when evaluating quality of life in clinical trials. Control Clin Trials 1990;11:169–179. · DOI
  26. Wiklund I. Aspects of quality of life in gastrointestinal disease: Some methodological issues. Scand J Gastroenterol 1995;208:129–132. · DOI
  27. Trus TL, Laycock WS, Branum GD, Waring JP, Hunter JG. Quality of life scores correlate poorly with subjective and objective measurements of gastroesophageal reflux. Gastroenterol 1997;112:A1480.
  28. Guyatt GH, Thompson PJ, Berman LB, Sullivan MJ, Townsend M, Jones NL, Pugsley SO. How should we measure function in patients with chronic heart and lung disease? J Chronic Diseases. 1985;38:517–524. · DOI · Paper page
  29. Rector TS, Kubo SH, Cohn JN. Patients’ Self-assessment of their cognitive heart failure: II: Content, reliability and validity of a new measure. The Minnesota Living with Heart Failure Questionnaire. Heart Failure 1987;3:198–209.
  30. Wiklund I, Comerford MB, Dimenas E. The relationship between exercise tolerance and quality of life in angina pectoris. Clin Cardiol 1991;14:204–208. · DOI
  31. Guyatt GH, Feeny DH, Patrick DL. Measuring Health-related quality of life. Ann Int Med 1993;118:622–629. · DOI · Paper page
  32. Stewart AL, Greenfield S, Hays RD, Wells K, Rogers WH, Berry SD, McGlynn EA, Ware JE. Functional status and well-being of patients with chronic conditions. Results from the Medical Outcomes Study. JAMA 1989;262:907–913. · DOI · Paper page
  33. Bayliss MS, Gandek B, Bungay KM, Sugano D, Hsu MA, Ware JE. A questionnaire to assess the generic and disease-specific health outcomes of patients with chronic hepatitis C. Qual Life Res 1998;7:39–55. · DOI · Paper page
  34. Ganz PA, Coscarelli A, Fred C, Kahn B, Plinski ML, Petersen L. Breast cancer survivors: Psychological concerns and quality of life. Breast Cancer Res Treat 1996;38:183–199. · DOI · Paper page
  35. Fletcher A, Gore S, Jones D, Fiztpatrick R, Spiegelhalter D, Cox D. Quality of life measures in health care. II: Design, analysis, and interpretation. Br Med J 1992;305:1145–1148. · DOI · Paper page
  36. Gill TM, Feinstein AR. A critical appraisal of the quality of quality of life measurements. JAMA 1994;272:619–626. · DOI · Paper page
  37. Patrick DL, Deyo RA. Generic and disease-specific measures in assessing health status and quality of life. Med Care 1989;27(Suppl 3):S217–S232. · DOI · Paper page
  38. Tandon PK, Stander H, Schwarz RPJ. Analysis of quality of life data from a randomized, placebo controlled heart-failure trial. J Clin Epidemiol 1989;42:955–962. · DOI
  39. Laupacis A, Wong C, Churchill D. The use of generic and specific quality-of-life measures in hemodialysis patients treated with Erythropoietin. Control Clin Trials 1991;121:68S–79S.
  40. Galmiche JP, Barthelemy P, Hamelin B. Treating the symptoms of gastro-oesophageal reflux disease: A double-blind comparison of Omeprazole and Cisapride. Aliment Pharmacol Ther 1997;11:765–773. · doi:10.1046/j.1365-2036.1997.00185.x
  41. Tarter RE, Switala J, Arria A, Plail J, Van Thiel D. Quality of life before and after orthotopic hepatic transplantation. Arch Int Med 1991;151:1521–1526. · DOI
  42. Bergner M, Rofhman ML. Health status measures: an overview and guide for selection. Ann Rev Public Health 1987;8:191–210. · DOI · Paper page
  43. Wiklund I. Quality of life and regulatory issues. Scand J Gastroenterol 1996;31(Suppl. 221):37–38. · doi:10.3109/00365529609095554
  44. Testa MA, Nackley JF. Methods for quality-of-life studies. Ann Rev Public Health 1994;15:535–559. · DOI · Paper page
  45. Guyatt GH, Kirshner B, Jaeschke R. Measuring health status: What are the necessary measurement properties? J Clin Epidemiol. 1992;45:1341–1345. · DOI · Paper page
  46. Hays R, Anderson R, Revicki DA. Assessing Reliability and Validity of Measurement in Clinical Trials. In: Staquet MJ, Hays RD, Fayers PM, eds. Quality of Life Assessment in Clinical Trials. New York, NY: Oxford University Press; 1998: 169–182.
  47. Fletcher A. Quality-of-life measurements in the evaluation of treatment: Proposed guidelines. Br J Clin Pharmacother 1995;39:217–222. · DOI
  48. Marquis P, Fayol C, Joire JE, Leplège A. Psychometric properties of a specific quality of life questionnaire in angina pectoris patients. Qual Life Res 1995;4:540–546. · DOI
  49. Jenkinson C, Ziebland S, Fitzpatrick R, Mowat A. Sensitivity to change of weighted and unweighted versions of two health status measures. Intl J Health Sciences 1991;2:189–194.
  50. Zimmerman M. Weighted versus unweighted life event scores: Is there a difference? J Human Stress. 1983;9:30–35. · doi:10.1080/0097840x.1983.9935028
  51. Fitzpatrick R, Fletcher A, Gore S, Jones D, Spiegel-halter D, Cox D. Quality of life measures in health care. I: Applications and issues in assessment. Br Med J 1992;305:1074–1077. · DOI · Paper page
  52. Kirschner B, Guyatt GH. A methodologic framework for assessing health indices. J Chronic Diseases 1985;38:27–36. · DOI · Paper page
  53. Guyatt G, Mitchell A, Irvine EJ, Singer J, Williams N, Goodacre R, Tompkins C. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterol 1989;96:804–810. · DOI · Paper page
  54. Eypasch E, Williams JI, Wood-Dauphinee S, Ure BM, Schmiilling C, Neugebauer E, Troidl H. Gastrointestinal Quality of Life Index: Development, validation and application of a new instrument. Br J Surg 1995;82:216–222. · DOI · Paper page
  55. Scharloo M, Kaptein AA, Weinman JA, Willems LNA, Rooijmans HGM. Physical and psychological correlates of functioning in patients with chronic obstructive pulmonary disease. J Asthma 2000;37:17–29. · DOI
  56. Faller H, Bulzebruck H, Drings P, Lang H. Coping, distress, and survival among patients with lung cancer. Arch Gen Psychiatry 1999;56:756–762. · DOI · Paper page
  57. Stockier MR, Osoba D, Corey P, Goodwin PJ, Tannock IF. Convergent, discriminative, and predictive validity of the Prostate Cancer Specific Quality of Life Instrument (PROSQOLI) assessment and comparison with Analogous Scales Form the EORTC QLQ-C30 and a trial-specific module. J Clin Epidemiol 1999;52:653–666. · DOI
  58. Feagan BG, McDonald JW, Rochon J, Laupacis A, Fedorak RN, Kinnear D, Saibil F, Groll A, Archambault A, Gillies R, Valberg B, Irvine JE, for the Canadian Crohn’s Relapse Prevention Trial Investigators. Low-dose Cyclosporine for the treatment of Crohn’s Disease. N Engl J Med 1994;330:1846–1851. · DOI · Paper page
  59. Guyatt GH, Walter S, Norman G. Measuring health status over time. Assessing the usefulness of evaluative instruments. J Chronic Diseases 1987;40:171–178. · DOI · Paper page
  60. Deyo RA, Diehr P, Patrick DL. Reproducibility and responsiveness of health status measures. Statistics and strategies for evaluation. Control Clin Trials 1991;12:S142–SI58. · DOI · Paper page
  61. Acquadro C, Jambon B, Ellis D, Marquis P. Languages and Translation Issues. In: Spilker B, ed. Quality of Life and Pharmacoeconomics in Clinical Trials. Second edition. Philadelphia, PA: Lippincott-Raven Publishers; 1996:575–585.
  62. Bullinger M, Anderson R, Cella D, Aaronson N. Developing and evaluating cross-cultural instruments from minimum requirements to optimal models. Qual Life Res 1993;2:451–459. · DOI · Paper page
  63. Hunt SM. Cross-cultural Issues in the Use of Quality of Life Measures in Randomized Clinical Trials. In: Staquet MJ, Hays RD, Fayers PM, eds. Quality of Life Assessment in Clinical Trials: Methods and Practice. New York, NY: Oxford University Press; 1998: 51–67.
  64. Bullinger M, Alonso J, Apolone G, Leplege A, Sullivan M, Wood-Dauphinee S, Gandek B, Wagner A, Aaronson N, Bech P, Fukuhara S, Kaasa S, Ware J. Jr. Translating health status questionnaires and evaluating their quality: the IQOLA project approach. International Quality of Life Assessment. J Clin Epidemiol 1998;51:913–923. · DOI · Paper page
  65. Gandek B, Ware J. Jr, Aaronson NK, Alonso J, Apolone G, Bjorner JB, Brazier J, Bullinger M, Fukuhara S, Kaasa S, Leplege A, Sullivan M. Tests of data quality, scaling assumptions, and reliability of the SF-36 in eleven countries: Results from the IQOLA project. J Clin Epidemiol 1998;51:1149–1158. · DOI · Paper page
  66. Spilker B. Quality of Life Trials. In: Spilker B, ed. Guide to Clinical Trials. New York, NY: Raven Press; 1991:370–378.
  67. Bernhard J, Cella DF, Coates CA, Fallowfield L, Ganz PA, Moinpour CM, Mosconi P, Osoba D, Simes J, Hürny C. Missing quality data in cancer clinical trials: Serious problems and challenges. Stat Med 1998;17:517–532. · DOI · Paper page
  68. Osoba D. Rationale for the timing of health-related quality-of-life assessments in oncological palliative therapy. Cancer Treat Rev 1996;22(Suppl.A):69–73. · doi:10.1016/s0305-7372(96)90066-3
  69. Rothman ML, Hedrick SC, Bulcroft KA, Hickam DH, Rubenstein LZ. The validity of proxy-generated scores as measures of patient health status. Med Care 1991;29:115–124. · DOI · Paper page
  70. Sneeuw KCA, Aaronson NK, Osoba D, Muller MJ, Hsu MA, Yung WK, Brada M, Newlands ES. The use of significant others as proxy raters of the quality of life of patients with brain cancer. Med Care 1997;35:490–506. · DOI · Paper page
  71. Sprangers MAG, Aaronson NK. The role of health care providers and significant others in evaluating the quality of life of patients with chronic disease: a review. J Clin Epidemiol 1992;45:743–760. · DOI · Paper page
  72. Testa MA, Hollenberg NK, Anderson RB, Williams GH. Assessment of quality of life by patient and spouse during antihypertensive therapy with Atenolol and Nifedipine gastrointestinal therapeutic system. Am J Hypertens 1991;4:363–373. · DOI
  73. Mathias SD, Bates MM, Pasta DJ, Cisternas MG, Feeny D, Patrick DL. Use of the health utilities index with stroke patients and their caregivers. Stroke 1997;28:1888–1894. · DOI
  74. Sneeuw KCA, Aaronson NK, Sprangers MAG, Detmar SB, Wever LDV, Schornagel JH. Value of caregiver ratings in evaluating the quality of life of patients with cancer. J Clin Oncol 1997;15:1206–1217. · DOI
  75. Sneeuw KCA, Aaronson NK, de Haan RJ, Limburg M. Assessing quality of life after stroke. The value and limitations of proxy ratings. Stroke 1997;28:1541–1549. · DOI · Paper page
  76. Stephens RJ, Hopwood P, Girling DJ, Machin D. Randomized trials with quality of life endpoints. Are doctor’s ratings of patients’ physical symptoms interchangeable with patients’ self-ratings? Qual Life Res. 1997;6:225–236. · DOI · Paper page
  77. Simes RJ, Greatorex V, Gebski VJ. Practical approaches to minimize problems with missing quality of life data. Stat Med 1998;17:725–737. · doi:10.1002/(sici)1097-0258(19980315/15)17:5/7<725::aid-sim817>3.0.co;2-1
  78. Lydick E, Epstein RS. Clinical Significance of Quality of Life Data. In: Spilker B, nted. Quality of Life and Pharmacoeconomics in Clinical Trials. Philadelphia, PA: Lippincott-Raven Publishers; 1996: 461–465.
  79. Chassany O, Duracinsky M. Ethics and clinical trials. Fundam Clin Pharmacol 1999;13:437–444. · DOI
  80. Rush DR, Stelmach J, Young TL, Kirchdoefer LJ, Scott-Lennox J, Holverson HE, Sabesin SM, Nicholas TA. Clinical effectiveness and quality of life with ranitidine vs placebo in gastroesophageal reflux disease patients: a clinical experience network (CEN) Study. J Fam Pract 1995;41:126–136.
  81. Juniper EF. Quality of life questionnaires: Does statistically significant = clinically important? J Allergy Clin Immunol. 1998;102:16–17. · DOI
  82. Lydick E, Epstein RS. Interpretation of quality of life changes. Qual Life Res 1993;2:221–226. · DOI · Paper page
  83. Offerhaus L. Measurement of the quality of life in clinical trials: in pursuit of the unapproachable. Eur J Clin Pharmacol 1991;40:205–208. · DOI
  84. Curran D, Fayers PM, Molengerghs G, Machin D. Analysis of Incomplete Quality of Life Data in Clinical Trials. In: Staquet MJ, Hays RD, Fayers PM, eds. Quality of Life Assessment in Clinical Trials. New York, NY: Oxford University Press; 1998:249–280.
  85. Fairclough D, Peterson H, Cella D, Bonomi P. Comparison of several model-based methods for analyzing incomplete quality of life data in cancer clinical trials. Stat Med 1998;17:781–796. · doi:10.1002/(sici)1097-0258(19980315/15)17:5/7<781::aid-sim821>3.0.co;2-o
  86. Hayden KA, Moinpour CM, Metch B, Feigl P, O’Brian RM, Green S, Osborne CK. Pitfalls in quality of life assessment: Lessons from a Southwest Oncology Group breast cancer clinical trial. Oncol Nurs Forum 1993;20:1415–1419.
  87. Olschewski M. Compliance with QoL assessment in multicentre German breast cancer trials. Stat Med 1998;17:571–575. · doi:10.1002/(sici)1097-0258(19980315/15)17:5/7<571::aid-sim804>3.0.co;2-o
  88. Wiklund I, Junghard O, Grace E, Talley NJ, Kamm M, Veldhuyzen van Zanten S, Paré P, Chiba N, Leddin DS, Bigard MA, Colin R, Schoenfeld P. Quality of life in reflux and dyspepsia patients. Psychometric documentation of a new disease-specific questionnaire (QOLRAD). Eur J Surg. 1998:83(Suppl.583):41–49.
  89. Machin D, Weeden S. Suggestions for the presentation of quality of life data from clinical trials. Stat Med 1998;17:711–724. · doi:10.1002/(sici)1097-0258(19980315/15)17:5/7<711::aid-sim816>3.0.co;2-h
  90. Troxel AB, Fairclough DL, Curran D, Hahn EA. Statistical analysis of quality of life with missing data in cancer clinical trials. Stat Med 1998;17:517–532. · DOI · Paper page
  91. Fairclough DL, Gelber RD. Quality of Life: Statistical Issues and Analysis. In: Spilker B, ed. Quality of Life and Pharmacoeconomics in Clinical Trials. Philadelphia, PA: Lippincott-Raven Publishers; 1996:427–435.
  92. Jaeschke R, Singer J, Guyatt GH. Measurement of Health Status: Ascertaining the Minimal Clinically Important Difference. Control Clin Trials 1989;10:407–415. · DOI · Paper page
  93. Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998;16:139–144. · DOI · Paper page
  94. Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific quality of life questionnaire. J Clin Epidemiol 1994;47:81–87. · DOI · Paper page
  95. Mahajan P, Pearlman D, Okamoto L. The effect of Fluticasone Propionate on functional status and sleep in children with asthma and on the quality of life of their parents. J Allergy Clin Immunol 1998;102:19–23. · doi:10.1016/s0091-6749(98)70050-8
  96. Samsa G, Edelman D, Rothman ML, Williams GR, Lipscomb J, Matchar D. Determining clinically important differences in health status measures. PharmacoEconomics 1999;15:141–155. · DOI · Paper page
  97. Wyrwich KW, Nienaber NA, Tierney WM, Wolinsky FD. Linking clinical relevance and statistical significance in evaluating intra-individual changes in health-related quality of life. Med Care 1999;37:469–478. · DOI · Paper page
  98. Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 Health Survey: Manual and Interpretation Guide. Boston, MA: The Health Institute, New England Medical Center; 1993.
  99. Thompson MS, Read JL, Hutchings HC, Paterson M, Harris ED. The cost effectiveness of Auranofin: Results of a randomized clinical trial. J Rheumatol 1988;15:35–42.
  100. Ware JE, Keller SD. Interpreting General Health Measures. In: Spilker B, ed. Quality of Life and Pharmacoeconomics in Clinical Trials. Philadelphia, PA: Lippincott-Raven Publishers; 1996:445–460.
  101. Juniper EF. The value of quality of life in asthma. Eur Respir Rev 1997;49:333–337.
  102. Liard F, Benichou AC, Gamand S, Lehert P. The effects of Naftidrofuryl on quality of life. Disease Manage Health Outcomes 1997;2(Suppl.1):71–78. · doi:10.2165/00115677-199700021-00014
  103. Altman DG, Bland JM. Absence of evidence is not evidence of absence. Br Med J 1995;311:485–486. · DOI · Paper page

Cited by

See all 365

Metadata

Authors
For the European Regulatory Issues on Quality of Life Assessment Group, Chassany, O., Sagnier, P., Marquis, P., Fullerton, S., & Aaronson, N.
Venue
Drug Information Journal
Publisher
Springer Science and Business Media LLC
Published
2002-01
Volume
36
Issue
1
Pages
209-238
ISSN
  • 0092-8615 (ISSN-L)
  • 2164-9200
DOI
10.1177/009286150203600127
OpenAlex
W2099563036
Cited by
365
References
8
FWCI
70.20
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Patient-Reported Outcomes: The Example of Health-Related Quality of Life—a European Guidance Document for the Improved Integration of Health-Related Quality of Life Assessment in the Drug Regulatory Process. https://app.cochat.ai/papers/10.1177/009286150203600127
The paper
For the European Regulatory Issues on Quality of Life Assessment Group, Chassany, O., Sagnier, P., Marquis, P., Fullerton, S., & Aaronson, N. (2002). Patient-Reported Outcomes: The Example of Health-Related Quality of Life—a European Guidance Document for the Improved Integration of Health-Related Quality of Life Assessment in the Drug Regulatory Process. Drug Information Journal. https://doi.org/10.1177/009286150203600127

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.